Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS) (ELISA)
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
A prospective cohort study, conducted in Canada, to prospectively evaluate whether the combination of clinicopathological criteria and the Oncotype DX DCIS score can identify a group of women at very low risk of local recurrence following breast conserving surgery who do not require breast radiation therapy. We plan to screen 809 consenting women who will have their tumour tissue specimen sent to Exact Sciences to assess their DCIS score. We anticipate that 526 women will have an Oncotype DX DCIS score with a predicted 10-year risk of local recurrence ≤10%, these women will be enrolled and followed as part of the study.
At each centre, all patients with DCIS referred to radiation oncology will be documented. When a physician identifies an eligible patient, the patient will be approached by the referring physician or delegate to voluntarily provide informed consent to participate in this study. Consenting patients will be registered through the Ontario Clinical Oncology Group's (OCOG) web-based registration system. A two-step registration/enrollment process will be implemented.
Data related to the patient demographics, surgery details, tumour characteristics and ECOG performance will be collected. The patient's tumour specimen will be sent for analysis to Exact Sciences. The DCIS score results will be sent to the referring physician. OCOG will also receive the DCIS score results. Patients will be followed yearly up to 10 years. Bilateral mammograms and breast exams will be performed annually. The study data will be verified by source documentation.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, Canada, V2S 0C2
- BC Cancer - Abbotsford Centre
-
Prince George, British Columbia, Canada, V2M 7E9
- BC Cancer - Centre for the North (Prince George)
-
Surrey, British Columbia, Canada, V3V 1Z2
- BC Cancer - Fraser Valley Centre
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer - Vancouver Centre
-
Victoria, British Columbia, Canada, V8R 6V5
- BC Cancer - Victoria
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- QE II HSC - Nova Scotia Cancer Centre
-
Sydney, Nova Scotia, Canada, B1P 1P3
- Cape Breton Cancer Centre
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Royal Victoria Regional Health Centre
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
Thunder Bay, Ontario, Canada, P7B 6V4
- Regional Cancer Care, Thunder Bay Regional Health Sciences Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Science Centre -Odette Cancer Centre
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network - Princess Margaret Cancer Centre
-
Windsor, Ontario, Canada, N8W 2X3
- Windsor Regional Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Hôpital Charles Le Moyne (CISSS de la Montérégie-Centre)
-
Montreal, Quebec, Canada, H4A 3J1
- McGill University Health Centre
-
Montreal, Quebec, Canada, H2L 4M1
- CHUM - Centre Hospitalier de L'Université de Montréal
-
Québec, Quebec, Canada, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec - Université Laval
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie- Centre-du-Québec (CIUSSS MCQ) - Trois-Rivières
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N4H4
- Saskatoon Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Prospective cohort study conducted in Canada in women with a low risk DCIS following breast conserving surgery who are candidates for radiation.
Eligibility status should be confirmed by the referring physician or delegate prior to enrollment. It is important that no exceptions are made to the eligibility criteria. Questions related to eligibility requirements and/or specific criteria should be addressed with OCOG prior to enrollment
Description
Inclusion Criteria:
-
Female patient > 45 years of age with DCIS without microinvasion.
-
Tumour size ≤ 2.5cm.
-
Treated by BCS with clear resection margins ≥ 2 mm or no residual disease on re-excision.*
* Patients with anterior margins and posterior margins ≥1 mm are eligible. Or if the dissection was confirmed to be taken to skin and down to fascia with no DCIS present at inked margins.
-
Oncotype DX DCIS score with a predicted 10-year risk of LR ≤10%.
Exclusion Criteria:
- Multifocal DCIS.
- History of any invasive breast cancer or non-invasive breast cancer in the ipsilateral breast.
- Synchronous or previous invasive or non-invasive breast cancer.
- Prior history of invasive cancer within the last 5 years, excluding non-melanoma skin cancers.
- ECOG performance status ≥3.
- Life expectancy <10 years.
- Geographic inaccessibility for follow-up.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Single Arm Cohort
Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ipsilateral local recurrence (LR)
Time Frame: 5 Year
|
Defined as recurrent invasive or in situ cancer in the ipsilateral breast |
5 Year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ipsilateral invasive local recurrence
Time Frame: 5 Year
|
defined as time from study registration to time of recurrent invasive cancer in the ipsilateral breast |
5 Year
|
|
Breast cancer recurrence-free interval (RFI)
Time Frame: 5 Year
|
defined as time from study registration to time of documented recurrent disease (ipsilateral breast (DCIS or invasive), regional, distant or death from breast cancer |
5 Year
|
|
Distant disease-free survival (DDFS)
Time Frame: 5 Year
|
defined as time from study registration to distant recurrence |
5 Year
|
|
Disease-free survival (DFS)
Time Frame: 5 Year
|
defined as time from registration to time of LR (DCIS or invasive), regional and distant recurrence, contralateral breast cancer, new primary (non-breast) and death from any cause |
5 Year
|
|
Overall survival (OS)
Time Frame: 5 Year
|
defined as time from registration to death of any cause |
5 Year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Eileen Rakovitch, M.D., Sunnybrook Research Institute, Sunnybrook Health Science
- Principal Investigator: Tim Whelan, M.D, Juravinski Cancer Centre
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OCOG-2021-ELISA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.